I. Hirsch

发表

Balancing benefit and risk of medicines: a systematic review and classification of available methodologies

L. Phillips, I. Tzoulaki, D. Ashby, 2014, Pharmacoepidemiology and drug safety.

The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies

I. Hirsch, J. Zangrilli, M. Goldman, 2017, Current medical research and opinion.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Blood Eosinophil Count Group Shifts and Kinetics in Severe, Eosinophilic Asthma.

I. Hirsch, J. Kreindler, F. Trudo, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Impact of Body Mass Index on Efficacy of Benralizumab in Patients with Severe, Uncontrolled Eosinophilic Asthma: Pooled Analysis of the SIROCCO and CALIMA Trials

I. Hirsch, F. Trudo, U. Martin, 2019, 60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

I. Pavord, G. Colice, M. Kraft, 2021, European Respiratory Journal.

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

C. Mcevoy, A. Falsey, S. Little, 2021, The New England journal of medicine.

(2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111.

S. Madhi, K. Dheda, P. Aley, 2020 .

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma

M. Humbert, I. Hirsch, D. Jackson, 2019, Advances in Therapy.

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.

E. Bleecker, J. FitzGerald, I. Hirsch, 2018, The Lancet. Respiratory medicine.

Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study.

L. Arnold, K. Chatamra, I. Hirsch, 2010, Clinical therapeutics.

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

J. Vekemans, P. Aley, M. Voysey, 2021, Nature Medicine.

Non‐parametric estimators of a monotonic dose–response curve and bootstrap confidence intervals

Günter Heimann, M. Dilleen, I. Hirsch, 2003, Statistics in medicine.

Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma

E. Bleecker, M. Wechsler, J. FitzGerald, 2018, European Respiratory Journal.

Appraising the quality of meta-analysis for breast cancer treatment in the adjuvant setting: A systematic review.

I. Hirsch, M. Chacón, P. Mandó, 2021, Cancer treatment and research communications.

Benralizumab Efficacy for Patients with Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma.

B. Chipps, I. Hirsch, F. Trudo, 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial.

L. Arnold, I. Hirsch, A. Ellis, 2012, Arthritis and rheumatism.

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

Lindsay N. Carpp, A. M. Stanley, M. Andrasik, 2023, npj Vaccines.

Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma.

J. Kline, G. Chupp, I. Hirsch, 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials

Lindsay N. Carpp, M. Fay, T. Fleming, 2020, Annals of Internal Medicine.

Structured Benefit–risk assessment: a review of key publications and initiatives on frameworks and methodologies

Shahrul Mt-Isa, Alexander Schacht, Mario Ouwens, 2016, Pharmaceutical statistics.

Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.

B. Chipps, I. Hirsch, F. Trudo, 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use.

Trung Nghia Tran, P. Pfeffer, A. Nanzer, 2022, The journal of allergy and clinical immunology. In practice.

Validation of the Daily Diary of Fatigue Symptoms—Fibromyalgia (DFS-Fibro)

T. Symonds, I. Hirsch, R. Arbuckle, 2013 .

A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated

Lindsay N. Carpp, M. Fay, J. Kublin, 2021, Annals of Internal Medicine.

Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials

Lindsay N. Carpp, M. Fay, J. Kublin, 2020, medRxiv.

Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

I. Hirsch, S. O'Quinn, Xiao Xu, 2019, Journal of asthma and allergy.

The role of the minimum clinically important difference and its impact on designing a trial

Christy Chuang-Stein, Simon Kirby, S. Kirby, 2011, Pharmaceutical statistics.

Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults

J. Kublin, A. Falsey, D. Follmann, 2023, JAMA network open.

Benefit–risk assessment in a post‐market setting: a case study integrating real‐life experience into benefit–risk methodology

Nan Wang, Davide Luciani, Ioanna Tzoulaki, 2014, Pharmacoepidemiology and drug safety.

Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma

I. Hirsch, S. O'Quinn, Xiao Xu, 2019, Journal of asthma and allergy.